



2023

## Unknown Rectal Lesions: A Case of Severe Proctitis Secondary to Mpox in the Setting of Concomitant HIV, Syphilis, HSV, and Chlamydia


Nicole Robertson MPH  
University of Kentucky, [nicole.robertson@uky.edu](mailto:nicole.robertson@uky.edu)

James Crosby DO  
University of Kentucky

Cynthia R. Young MD, MSc  
University of Kentucky

Anne E. Sayers MD  
University of Kentucky

Nicholas J. Van Sickles MD  
University of Kentucky  
Follow this and additional works at: <https://uknowledge.uky.edu/emrs>

 Part of the [Diagnosis Commons](#), [Internal Medicine Commons](#), [Therapeutics Commons](#), and the [Virus Diseases Commons](#)

[Right click to open a feedback form in a new tab to let us know how this document benefits you.](#)

### Recommended Citation

Robertson, Nicole MPH; Crosby, James DO; Young, Cynthia R. MD, MSc; Sayers, Anne E. MD; and Van Sickles, Nicholas J. MD (2023) "Unknown Rectal Lesions: A Case of Severe Proctitis Secondary to Mpox in the Setting of Concomitant HIV, Syphilis, HSV, and Chlamydia," *ePublications of Emerging Medical Research Scholars*: Vol. 1, Article 1.

DOI: <https://doi.org/10.13023/emrs.2023.01>

Available at: <https://uknowledge.uky.edu/emrs/vol1/iss1/1>

This Case Study is brought to you for free and open access by the College of Medicine at UKnowledge. It has been accepted for inclusion in ePublications of Emerging Medical Research Scholars by an authorized editor of UKnowledge. For more information, please contact [UKnowledge@lsv.uky.edu](mailto:UKnowledge@lsv.uky.edu).

---

## Unknown Rectal Lesions: A Case of Severe Proctitis Secondary to Mpox in the Setting of Concomitant HIV, Syphilis, HSV, and Chlamydia

### Cover Page Footnote

This study was supported by the Infectious Disease Society of America 2022-2023 Grant for Emerging Researchers/Clinicians Mentorship (G.E.R.M.) program (NMR).

## **Unknown Rectal Lesions: A Case of Severe Proctitis Secondary to Mpox in the Setting of Concomitant HIV, Syphilis, HSV, and Chlamydia**

Nicole M Robertson MPH<sup>1</sup>, James Crosby DO<sup>2</sup>, Cynthia R. Young MD, MSc<sup>2</sup>, Anne E Sayers MD<sup>3</sup>, Nicholas J. Van Sickles MD<sup>2</sup>

<sup>1</sup> University of Kentucky College of Medicine, Lexington, KY, USA

<sup>2</sup> Division of Infectious Diseases, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA

<sup>3</sup> Division of Hospital Medicine, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY, USA

### **Correspondence:**

Nicole Robertson

University of Kentucky College of Medicine

William R. Willard Medical Education Building, MN 150

Lexington KY, USA 40536-0298

Email: [nicole.robertson@uky.edu](mailto:nicole.robertson@uky.edu)

**Key Phrases:** rectal lesion, diagnosis, treatment Mpox, HIV, syphilis, sexually transmitted infections

**Disclaimers:** None

**Word Count:** 997

**Table and Figure Count:** 3

**Sources of Support:** This study was supported by the Infectious Disease Society of America 2022-2023 Grant for Emerging Researchers/Clinicians Mentorship (G.E.R.M.) program (NMR).

**Conflicts of Interest:** We have no competing interests to declare.

**ABSTRACT****Introduction:**

Mpox emerged as a public health crisis with limited research describing co-occurring HIV and sexually transmitted infections (STIs). We present a case of severe proctitis secondary to Mpox with concomitant HIV (Human Immunodeficiency Virus), syphilis, HSV (Herpes Simplex Virus), and chlamydia and review presentation, diagnosis, treatment, and prevention of Mpox with concurrent STIs.

**Case Presentation:**

34-year-old male living with HIV (LWH) presenting with worsening rectal pain, multiple anal papules, and fever. His laboratory workup revealed simultaneous positive results for orthopoxvirus, chlamydia, and HSV-1 PCR. We initiated tecovirimat due to rectal involvement and uncontrolled pain. He subsequently developed lesions on hands as rectal pain improved. He completed tecovirimat treatment and the lesions cleared by outpatient follow-up.

**Discussion:**

Among published studies of Mpox patients, 40% were LWH, and a significant percent were found to have co-occurring gonorrhea (23%), chlamydia (20%), syphilis (8%), and HSV (1%) with presentations including fever (62%), lymphadenopathy (49%), malaise (39%), and rectal pain (25%). We recommend Mpox and full STI diagnostic testing for unknown anogenital lesions and early treatment should be considered. Early initiation of Tecovirimat treatment should be considered in severe disease, immune deficiency, or those at high-risk for serious sequelae, in accordance with CDC guidelines.

**Learning Points:**

- Identify the differential diagnosis for unknown rectal lesions
- Describe the clinical presentation of Mpox
- Summarize the diagnostic approach and interpretation of diagnostic results
- Identify treatment options and considerations by patient populations
- Review preventative strategies and high-risk populations for Mpox transmission

**INTRODUCTION**

Mpox is a viral zoonotic orthopoxvirus first identified in humans in 1970 in the Democratic Republic of Congo.<sup>1</sup> Outbreaks were mainly limited to Africa until a 2003 outbreak infecting 70 Americans from prairie dog contact.<sup>2</sup> A 2017 Mpox outbreak in Nigeria signaled its reemergence in West Africa but was predominantly among young adult males and attributed to person-to-person secondary transmission. Due to travel, genome mutations, and international gatherings, Mpox emerged as a public health crisis in 2022. Growing published case series and outbreak reports have described concurrent HIV (Human Immunodeficiency Virus) and Mpox; however, few have reported cases of other concurrent STIs with Mpox.<sup>3,4,5,6,7</sup> As Mpox prevalence increases, comparing Mpox presentation with similar appearing STIs has increasing clinical importance. We present a case of severe proctitis secondary to Mpox with concomitant HIV, syphilis, HSV (Herpes Simplex Virus), and chlamydia treated with tecovirimat and review current literature on presentation, diagnosis, treatment, and prevention of Mpox with concurrent STIs.

## CASE PRESENTATION

A 34-year-old male LWH since 2018 with intermittent antiretroviral therapy (ART) adherence and a history of prior STIs presented to the Emergency Department (ED) with severe, burning rectal pain and chills for 3 days. He endorsed anal sex with multiple partners and intermittent condom use over the last year. Examination revealed three gray/white, shallow perirectal ulcerations with drainage. He was diagnosed with hemorrhoids, and testing for syphilis and HSV were performed. At discharge, he was presumptively treated with valacyclovir and pain medications.

He re-presented to ED two days later with worsening rectal pain, chills, and new onset fever (Tmax 103°F) with diarrhea. On re-examination there was inguinal lymphadenopathy and 10 white papules surrounding the anal canal. Labs revealed leukocytosis, a positive rectal swab for HSV-1 PCR, absolute CD4 count 295, and HIV viral load 66,149 copies/mL (Table 1). RPR titers from the prior ED visit were elevated compared to prior (Table 1). CT pelvis revealed extensive rectal wall thickening and no drainable collection.

On hospital day (HD) 2, he continued to endorse severe, constant rectal pain. On HD 3, infectious disease consultants recommended Mpox PCR testing, a 21-day doxycycline course for chlamydia treatment, and single dose intramuscular penicillin G for syphilis treatment. Mpox PCR testing was performed due to the patient's known Mpox risk factors, systemic symptoms consistent with Mpox, and increased local transmission. On HD 4, tecovirimat was initiated twice daily for 14 days due to extensive rectal involvement, immune deficiency, and significant pain management requiring hospitalization. On HD 8, he developed lesions on his hands and fingers, and Mpox diagnostic testing resulted positive (Figure 1). He noted substantial

improvement in pain with tecovirimat treatment. Due to unstable housing and Mpox isolation guidelines, he was discharged after tecovirimat completion. On outpatient follow-up he denied residual rectal pain and had clearing of the lesions.

## **DISCUSSION**

Mpox emerged in the U.S. to epidemic levels with nearly 30,000 cases and 20 deaths reported as of January 2023.<sup>8</sup> We present the first known case of Mpox with four co-occurring STIs and complete resolution of lesions with tecovirimat. Growing U.S. and global cross-sectional studies suggest HIV and other STIs are highly prevalent among persons diagnosed with Mpox.<sup>4,6,9,10</sup> A recent case report outlined Mpox with co-occurring gonorrhea and chlamydia with proctitis and absence of anogenital lesions.<sup>7</sup> CDC data found that among 1,969 U.S. persons with Mpox, 38% had HIV and 41% had an STI diagnosed in the preceding year.<sup>4</sup> Furthermore, an international case series found Mpox co-infection common with HIV (39%) or other STIs (29%).<sup>6</sup> Among published studies of Mpox with co-occurring STIs globally, we found STIs included HIV (40%), gonorrhea (23%), chlamydia (20%), syphilis (8%), and HSV (1%) (Table 2). There is more robust surveillance of Mpox and STI data in the U.S. rather than global settings, which highlights a limitation to this study and greater need for Mpox data reporting in global populations.

### ***Signs and Symptoms***

The incubation period of Mpox is 5-21 days with symptoms lasting 2-4 weeks.<sup>2</sup> We found in published Mpox cases with co-occurring STIs, clinical presentation included fever (62%), lymphadenopathy (49%), malaise (39%), headache (28%), and rectal pain (25%) (Table 2).

Furthermore, this patient initially presented with white anorectal papules progressing to bilateral hand and arm vesicles. Literature review found 95% cases reported skin lesions in anogenital (67%), extremities (39%), trunk (30%), and palms/soles (16%) areas. Lesions varied in magnitude from singular to thousands of lesions and character including macules, papules, vesicles, or pustules that coalesced to large sections.

### ***Diagnosis***

The differential diagnosis of unknown rectal lesions can include syphilis, gonorrhea, chlamydia, HSV, malignancy, and Mpox. This patient initially presented with multiple rectal papules and prior STI diagnoses. However, Desgranges and colleagues document a patient with Mpox with two co-occurring presenting with severe proctitis and no anogenital lesions.<sup>7</sup> The wide array of documented Mpox presentations can make distinguishing between STIs clinically difficult without further diagnostic testing. We recommend orthopoxviral PCR and a full STI screening panel for all sexually active individuals with unknown anogenital lesions or proctitis, and especially among populations with recent or high-risk exposure, consistent with CDC guidelines. In the setting of little to no clinical improvement despite concurrent STI treatment, pretest probability of Mpox diagnosis increases.

### ***Treatment***

Typically, Mpox is a self-limited condition, treated with supportive care. However, underlying immune deficiencies have been associated with worse patient outcomes.<sup>2</sup> This patient was empirically treated with tecovirimat due to uncontrolled HIV, rectal lesions with risk of severe



sequelae, and uncontrolled rectal pain.<sup>13</sup> Providers should consider referral to Study of Tecovirimat for Human Mpox Virus (STOMP) sites for treatment.<sup>14</sup> If not feasible, we recommend initiating tecovirimat in patients with uncontrolled pain, severe disease, or involvement of areas (*i.e.*, pharynx, anogenital, eye) prone to serious sequelae. Tecovirimat is administered for 14 days and is available in oral and IV formulation and is a weak inhibitor of CYP2C8 and CYP2C19, so providers should verify drug interactions.<sup>11,13,15</sup> Mpox treatment should also consider multi-modal pain management due to documented lesion-associated pain.

### ***Prevention***

Currently, two FDA-approved vaccines have been administered as pre- or post-exposure prophylaxis to high-risk populations to prevent Mpox transmission.<sup>2</sup> Specifically, CDC recommends vaccination for gay, bisexual, and other men who have sex with men and transgender, non-binary, and gender-diverse people who have any of the following risk factors: multiple partners, sex at a commercial venue, a new (within 6 months) STI diagnosis, planned attendance at large gatherings, or anticipated/current partners with these risk factors.<sup>16</sup> We recommend following CDC guidance on Mpox vaccination.

### **CONCLUSION**

As the prevalence of Mpox with concurrent STIs increases globally, we present a rare case of Mpox in a patient LWH with several co-occurring STIs. In the setting of unknown anogenital lesions, we recommend testing for Mpox and STIs due to the varied and overlapping clinical presentations and shared risk factors. Mpox should be included on the differential diagnosis

among other STIs and utilizing epidemiological data may be helpful in delineating and expanding this differential diagnosis during Mpox outbreaks. Early treatment and potential hospitalization in patients with severe disease, immune deficiency, or high-risk for serious sequelae with tecovirimat may prevent morbidity and mortality.

## REFERENCES

1. Ladnyj ID, Ziegler P, Kima E. A human infection caused by monkeypox virus in Basankusu Territory, Democratic Republic of the Congo. *Bull World Health Organ* 1972;46:593-597.
2. World Health Organization. Monkeypox Key Facts. 2022. Available at: <https://www.who.int/news-room/fact-sheets/detail/monkeypox>. Accessed January 7, 2023.
3. Bížová B, Veselý D, Trojánek M, Rob F. Coinfection of syphilis and monkeypox in HIV positive man in Prague, Czech Republic. *Travel Med Infect Dis*. 2022 Sep-Oct;49:102368. doi: 10.1016/j.tmaid.2022.102368.
4. Curran KG, Eberly K, Russell OO, et al. HIV and Sexually Transmitted Infections Among Persons with Monkeypox — Eight U.S. Jurisdictions, May 17–July 22, 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:1141–1147. doi: 10.15585/mmwr.mm7136a1.
5. Ogoina D, Iroezindu M, James HI, Oladokun R, Yinka-Ogunleye A, Wakama P, Otike-Odibi B, Usman LM, Obazee E, Aruna O, Ihekweazu C. Clinical Course and Outcome of Human Monkeypox in Nigeria. *Clin Infect Dis*. 2020 Nov 5;71(8):e210-e214. doi: 10.1093/cid/ciaa143.
6. Thornhill JP, Barkati S, Walmsley S, et al. SHARE-net Clinical Group. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. *N Engl J Med*. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323.

7. Desgranges F, Glampedakis E, Christinet V, ... Opota O, Cavassini M. Rectal shedding of monkeypox virus in a patient coinfecting with *Chlamydia trachomatis* and *Neisseria gonorrhoeae*: a case report. *J Med Case Rep*. 2023 Mar 6;17(1):94. doi: 10.1186/s13256-023-03826-z.
8. Centers of Disease Control and Prevention (CDC). 2022 Monkeypox Outbreak Global Map. (2022). Available at: <https://www.cdc.gov/poxvirus/monkeypox/response/2022/index.html>. Accessed January 7, 2023.
9. Angelo KM, Smith T, Camprubí-Ferrer D, Balardi-Sarasola L,...GeoSentinel Network Collaborators. Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study. *Lancet Infect Dis*. 2022 Oct 7:S1473-3099(22)00651-X. doi: 10.1016/S1473-3099(22)00651-X.
10. Iñigo Martínez J, Gil Montalbán E, Jiménez Bueno S, et al. Monkeypox outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April to 16 June 2022. *Euro Surveill*. 2022 Jul;27(27):2200471. doi: 10.2807/1560-7917.ES.2022.27.27.2200471.
11. Perez Duque M, Ribeiro S, Martins JV, et al. Ongoing monkeypox virus outbreak, Portugal, 29 April to 23 May 2022. *Euro Surveill*. 2022;27(22):2200424. doi: 10.2807/1560-7917.ES.2022.27.22.2200424.
12. Antinori A, Mazzotta V, Vita S, et al. INMI Monkeypox Group. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. *Euro Surveill*. 2022 Jun;27(22):2200421. doi: 10.2807/1560-7917.ES.2022.27.22.2200421.

13. Centers of Disease Control and Prevention (CDC). Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children. (2022). Available at: <https://www.cdc.gov/poxvirus/monkeypox/pdf/Tecovirimat-IND-Protocol-CDC-IRB.pdf>. Accessed January 7, 2023.
14. Study of Tecovirimat for Human Monkeypox Virus (STOMP). Clinical Trials.gov. (2023) Available at: <https://clinicaltrials.gov/ct2/show/NCT05534984>. Accessed January 7, 2023.
15. Food and Drug Administration. Highlights of Prescribing Information TPOXX. (2022). Available at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/214518s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214518s000lbl.pdf). Accessed January 7, 2023.
16. Centers of Disease Control and Prevention (CDC). Monkeypox Components of the U.S. National Vaccination Strategy. (2022c). Available at: <https://www.cdc.gov/poxvirus/monkeypox/interim-considerations/overview.html>. Accessed January 7, 2023.

## TABLES AND FIGURES

**Table 1.** Patient lab values on diagnostic workup

Hospital Day Lab Collected	Lab	Lab Value	Reference Range
<b>Hematology and Chemistry</b>			
1	WBC	13,310/uL	3,700-10,300/uL
1	Hemoglobin	11.8 g/dL	13.7- 17.5 g/dL
1	Sodium	132 mmol/L	136-145 mmol/L
1	Potassium	3.7 mmol/L	3.7-4.8 mmol/L
1	Creatine	0.83 mg/dL	0.8-1.3 mg/dL
<b>Microbiology</b>			
1	Blood culture (two sets)	No growth at day 5	No growth
1	Urine culture	No growth at 30 hrs	No growth
<b>Infectious Disease</b>			
2	Absolute CD4 count (% CD4)	295 (16%)	490-1730 cells/ uL
2	HIV Viral Load	66,149 copies/mL	<40 copies/mL
Prior encounter	Rapid Plasma Reagin	Reactive	Nonreactive
Prior encounter	Rapid Plasma Reagin Titer	1:16 (1:4 10 months prior)	<1:1
Prior encounter	HSV-1 PCR	Detected	Not detected
2	Chlamydia trachomatis DNA PCR	Detected	Not detected
2	Neisseria gonorrhoea DNA PCR	Not detected	Not detected
3	Lymphogranuloma venereum IgG antibodies	1:64	<1.1
3	Lymphogranuloma venereum IgG antibodies	<1:10	<1:10
3	Orthopoxvirus (including Mpox) PCR	Detected	Not detected

**Table 2.** Literature review of published case reports, case series, and cross-sectional studies of populations diagnosed with Mpox and co-occurring sexually transmitted infections

	Ogoina <i>et al.</i> , 2020 <sup>5</sup>	Perez Duque <i>et al.</i> , 2022 <sup>10</sup>	Iñigo Martínez <i>et al.</i> , 2022 <sup>9</sup>	Thornhill <i>et al.</i> , 2022 <sup>6</sup>	Antinori <i>et al.</i> , 2022 <sup>11</sup>	Angelo <i>et al.</i> , 2022 <sup>8</sup>	Curran <i>et al.</i> , 2022 <sup>4</sup>	Bížová <i>et al.</i> , 2022 <sup>3</sup>	Overall
<b>Study Design</b>	Cross-sectional	Case Series	Cross-sectional	Case series	Case series	Cross-sectional	Cross-sectional	Case report	
<b>Time Period</b>	2017	Apr-May 2022	Apr-Jun 2022	Apr-Jun 2022	May 2022	May-Jul 2022	May-Jul 2022	2022	
<b>Location</b>	Nigeria	Portugal	Spain	Global	Italy	Global	U.S.	U.S.	
<b>Male Sex Assigned at Birth % (n)</b>	81% (17)	100% (27)	99% (503)	>99% (527)	100% (4)	100% (226)	74% (1466)	100% (1)	<b>84%</b> (2771/3284)
<b>Men having Sex with Men % (n)</b>	--	95% (18)	93% (397)	98% (519)	100% (4)	92% (208)	--	100% (1)	<b>95%</b> (1147/1205)
<b>Mpox Cases (n)</b>	21	27	508	528	4	226	1969	1	<b>3284</b>
<b>Sexually Transmitted Infections % (n)</b>									
<b>STI Sample Size</b>	17	27	508	See Below <sup>1</sup>	4	193	1969	1	
<b>HIV</b>	6% (1)	52% (14)	44% (225)	41% (89/218)	50% (2)	48% (92)	38% (755)	100% (1)	<b>40%</b> (1179/2953)
<b>Chlamydia</b>	--	--	--	5% (20/377)	--	1% (1)	25% (489)	--	<b>20%</b> (510/2539)
<b>Gonorrhea</b>	--	--	--	8% (32/377)	--	5% (9)	28% (546)	--	<b>23%</b> (587/2539)
<b>Syphilis</b>	18% (3)	--	--	9% (33/377)	75% (3)	3% (5)	8% (165)	100% (1)	<b>8%</b> (210/2561)
<b>Herpes Simplex Virus</b>	--	--	--	1% (3/337)	--	1% (1)	--	--	<b>1%</b> (4/530)
<b>Multiple STIs</b>	--	--	--	1% (5/377)	--	1% (1)	21% (420)	--	<b>17%</b> (426/2539)
<b>Symptoms % (n)</b>									
<b>Symptoms Sample Size</b>	21	27	508	528	4	226	1969	1	
<b>Fever</b>	90% (19)	48% (13)	64% (324)	63% (330)	50% (2)	58% (131)	--	100% (1)	<b>62%</b> (820/1315)
<b>Sweats</b>	62% (13)	--	--	--	--	--	--	--	<b>62%</b> (13/21)
<b>Lymphadenopathy</b>	62% (13)	52% (14)	44% (225)	56% (295)	--	36% (82)	50% (983)	100% (1)	<b>49%</b> (1613/3280)
<b>Malaise</b>	62% (13)	26% (7)	36% (185)	41% (216)	--	41% (93)	--	--	<b>39%</b> (514/1310)
<b>Headache</b>	57% (12)	26% (7)	32% (162)	--	--	15% (35)	--	--	<b>28%</b> (216/782)
<b>Odynophagia</b>	--	--	28% (143)	--	--	--	--	--	<b>28%</b> (143/508)
<b>Myalgia</b>	24% (5)	19% (5)	--	31% (165)	25% (1)	14% (32)	--	--	<b>26%</b> (208/806)
<b>Proctitis/Rectal Pain</b>	--	--	16% (81)	14% (75)	--	15% (33)	31% (609)	--	<b>25%</b> (798/3231)
<b>Pharyngitis</b>	41% (9)	--	--	21% (113)	--	24% (54)	--	--	<b>23%</b> (176/776)
<b>Cough</b>	19% (4)	--	--	--	--	--	--	--	<b>19%</b> (4/21)
<b>Rectal Bleeding</b>	--	--	--	--	--	4% (8)	16% (322)	--	<b>15%</b> (330/2195)
<b>Pruritis</b>	67% (14)	--	--	--	--	8% (18)	--	--	<b>13%</b> (32/247)
<b>Lesions % (n)</b>									
<b>Any site</b>	100% (21)	26% (7)	98% (498)	95% (500)	100% (4)	99% (221)	--	100% (1)	<b>95%</b> (1252/1312)
<b>Anogenital</b>	48% (10)	22% (6)	71% (359)	73% (383)	100% (4)	55% (124)	--	100% (1)	<b>67%</b> (887/1315)
<b>Extremities</b>	--	--	44% (222)	--	75% (3)	26% (56)	--	--	<b>39%</b> (281/725)
<b>Trunk</b>	--	--	31% (159)	--	50% (2)	27% (57)	--	--	<b>30%</b> (218/727)
<b>Face/Head</b>	--	--	35% (177)	25% (134)	--	24% (51)	--	100% (1)	<b>29%</b> (363/1250)
<b>Oral</b>	52% (11)	0% (0)	0% (0)	23% (50)	0% (0)	19% (43)	--	100% (1)	<b>21%</b> (105/491)
<b>Palms/Soles</b>	--	--	24% (124)	10% (51)	25% (1)	11% (24)	--	--	<b>16%</b> (200/1265)

<sup>1</sup> Sample sizes for each reported sexually transmitted infection (STI) in the Thornhill et al. study differed based on number of participants data was collected from. The number of participants included in each STI category are included below.

Figure 1. Patient presentation and hospital course timeline

